Menu Back toArtificial-Intelligence-The-Future-of-Regulatory-Affairs
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2018 Global Annual Meeting
Artificial Intelligence: The Future of Regulatory Affairs
Linda Bowen, MSc, RAC
- Head of Regulatory Policy and Intelligence
- Seattle Genetics, United States
This session will focus on the various aspects of artificial intelligence (AI) currently incorporated in regulatory processes as well a futuristic look at what it can do for the RA function. Case studies and lessons learned on AI pilots within the biopharma and medical device industry will be highlighted as well as FDA's perspective on the future of AI.
Learning Objective : Identify obstacles in developing an artificial intelligence pilot for regulatory decision making; Discuss lessons learned on a large pharma's groundbreaking artificial intelligence pilot; Analyze the integration of artificial intelligence into regulatory processes including information management.
Regulatory 2.0: The Future of Regulatory Affairs and Advanced Technologies
- Deloitte, United States
Exploring New Ways of Working Using Artificial Intelligence: Proof of Concept Pilot
Dany De Grave
- Senior Director, Innovation Programs & External Networks
- Sanofi Pasteur, United States
Bakul Patel, MBA, MS
- Director, Digital Health Division, CDRH
- FDA, United States